Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) EBT (2016 - 2025)

Purple Biotech has reported EBT over the past 6 years, most recently at -$8.1 million for Q4 2022.

  • Quarterly EBT fell 274.62% to -$8.1 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $7.4 million through Dec 2022, down 57.22% year-over-year, with the annual reading at $26.9 million for FY2025, 136.17% up from the prior year.
  • EBT was -$8.1 million for Q4 2022 at Purple Biotech, down from $4.8 million in the prior quarter.
  • Over five years, EBT peaked at $8.1 million in Q4 2020 and troughed at -$8.1 million in Q4 2022.
  • The 5-year median for EBT is $3.4 million (2022), against an average of $3.6 million.
  • Year-over-year, EBT skyrocketed 134.05% in 2020 and then crashed 274.62% in 2022.
  • A 5-year view of EBT shows it stood at $3.2 million in 2018, then rose by 7.87% to $3.4 million in 2019, then skyrocketed by 134.05% to $8.1 million in 2020, then plummeted by 42.73% to $4.6 million in 2021, then crashed by 274.62% to -$8.1 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's EBT are -$8.1 million (Q4 2022), $4.8 million (Q3 2022), and $3.4 million (Q2 2022).